17-Acetyl-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-11-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17-Acetyl-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-11-one
• 化学式: C₂₁H₃₀O₃
• 分子量: 330.5
• InChiKey: UIGQYEDQWMJFEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase
  申请人：Banner Lester Bruce

  公开号：US20070049632A1

  公开（公告）日：2007-03-01

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  本文提供了以下式(I)的化合物： 以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如II型糖尿病和代谢综合征等疾病是有用的。
• Aryl sulfonyl piperidines
  申请人：Gillespie Paul

  公开号：US20060199816A1

  公开（公告）日：2006-09-07

  Provided herein are compounds of the formula (1): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  本文提供了以下式（1）的化合物： 以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如II型糖尿病和代谢综合征等疾病是有用的。
• Pyrazoles
  申请人：Gillespie Paul

  公开号：US20060223852A1

  公开（公告）日：2006-10-05

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  本文提供了公式（I）的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗疾病，例如II型糖尿病和代谢综合征等，具有用处。
• Selective 11beta-HSD inhibitors and methods of use thereof
  申请人：——

  公开号：US20030148987A1

  公开（公告）日：2003-08-07

  Methods for treating glucocorticoid associated states using selective 11&bgr;-HSD1-dehydrogenase, 11&bgr;-HSD1-reductase and 11&bgr;-HSD2 dehydrogenase modulating compounds are described.

  描述了使用选择性 11&bgr;-HSD1-脱氢酶、11&bgr;-HSD1-还原酶和 11&bgr;-HSD2 脱氢酶调节化合物治疗糖皮质激素相关状态的方法。
• Selective 11beta HSD inhibitors and methods of use thereof
  申请人：Morris J. David

  公开号：US20060148725A1

  公开（公告）日：2006-07-06

  Methods for treating glucocorticoid associated states using selective 11β-HSD1-dehydrogenase, 11β-HSD1-reductase and 11β-HSD2 dehydrogenase modulating compounds are described.

  描述了使用选择性 11β-HSD1-脱氢酶、11β-HSD1-还原酶和 11β-HSD2 脱氢酶调节化合物治疗糖皮质激素相关状态的方法。